Niki BioSolutions Resolves Nasdaq Minimum Bid Price Deficiency, Regains Full Compliance
NIKI sits 50% above its 52-week low of $6 on light trading volume (0.1× avg).
Summary
Niki BioSolutions regained compliance with Nasdaq's minimum bid price rule, closing the deficiency matter. The stock held above $1.00 for 10 consecutive days through August 3, 2026.
Key Events · Legal and Risk Events · NIKI
-
Nasdaq Compliance Regained
On August 4, 2026, Nasdaq confirmed that the company's stock closed at or above $1.00 for 10 consecutive business days—from July 21 through August 3, 2026—satisfying the minimum bid price requirement under Rule 5550(a)(2).
-
Delisting Threat Resolved
The deficiency notice issued on March 5, 2026, is now closed. With a deadline of September 1, 2026, to regain compliance, achieving it early eliminates the risk of delisting from the Nasdaq Capital Market.
-
Stock Price Recovery
Reflecting improved market confidence, the stock price has recovered from below $1.00 to $8.99 as of today, well above the compliance threshold.
Analysis · NIKI · Industrial Applications And Services
A critical delisting threat has been lifted. Nasdaq confirmed compliance after the stock traded above $1.00 for 10 consecutive days, closing the matter. This removes the immediate delisting risk that had been a major overhang since the deficiency notice in March 2026.
At the time of this filing, NIKI was trading at $8.99 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.3M. The 52-week trading range was $6.00 to $44.70. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.